



Figura 28.
Adenocarcinoma de endometrio sometido a quimioterapia. Enfermedad residual peritoneal en pared anterior del abdomen y pelvis menor en PET-FDG.



Figura 29.
Cáncer de útero. Adenopatías prevertebrales a ambos lados de la línea media abdominal y supraclavicular izquierda.

el cáncer de ovario. Varios casos estudiados en nuestro Centro mediante PET-FDG, son mostrados en las Figuras 22,24-29. Hebart y cols (57) practican estudio PET-FDG en 2 mujeres con coriocarcinoma metastásico, una de ellas con tromboembolismo secundario. La PET-FDG en este caso fue la única técnica no invasiva capaz de diferenciar entre coágulos sanguíneos y tumor. Además ayudó a localizar el tejido tumoral maligno ante elevación de beta-HCG tras quimioterapia y estudio de extensión negativo.

Bibliografía

1. Carreras JI. La Tomografía por Emisión de Positrones en Oncología. Instituto de España. Real Academia Nacional de Medicina. 1995.
2. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. *J Nucl Med* 1996; 37: 1042-1047.
3. Zincke M, Avril N, Dose J. PET imaging of breast cancer: Comparison between FDG uptake vs. histology and expression of the glucose transporter protein Glut-1. *J Nucl Med* 1997; 38: 69.
4. Bassa P, Kim E., Inoue T, Wong FCL, Korkmaz M, Yang DJ, et al. Evaluation of preoperative chemotherapy using PET with Fluorine-18-fluorodeoxyglucose in breast cancer. *J Nucl Med* 1996; 37: 931-938.
5. Avril N, Dose J, Jänicke F, Bense S, Ziegler S, Laubenbacher C, et al. Metabolic characterization of breast tumors with PET using FDG. *J Clin Oncol* 1996; 14: 1848-1857.
6. Dose J, Avril N, Ziegler S, Bense S, Romer W, Weber W, et al. Ranking of PET with FDG in the diagnosis of carcinomas of the breast. *Geburtsh Frauenheilk* 1997; 57 (6): 315-320.
7. Avril N, Bense S, Ziegler SI, Dose J, Weber W, Laubenbacher C, et al. Breast imaging with FDG PET: quantitative image analysis. *J Nucl Med* 1997; 38(8): 1186-91.
8. Crippa F, Agresti R, Pascali C. FDG - PET in the presurgical staging of the axilla in breast cancer.(Abstract). *Eur J Nucl Med* 1997; 24: 882.
9. Crippa F, Agresti R, Seregni E, Greco M, Pascali C, Bogni A, et al. Prospective evaluation of FDG - PET in presurgical staging of the axilla in breast cancer. *J Nucl Med* 1998; 39(1): 4-8.
10. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR. Axillary lymph node metastases: screening with FDG -PET. *Radiology*, 1997; 203: 323-327.
11. Crippa F, Agresti R, Delle Donne V. The contribution of positron emission tomography (PET) with 18F-Fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan. *Tumori* 1997; 83: 542-543.
12. Hubner KF, Smith GT, Buonocore E. The potential of F-18-FDG PET for the management of patients with breast cancer. *J Nucl Med* 1997; 38: 69.
13. Utech CI, Young CS, Winter PF. Prospective evaluation of FDG - PET in breast cancer for staging of the axilla related to surgery and immunocytochemistry. *Eur J Nucl Med* 1996; 23: 1588-1593.
14. Romer W, Avril N, Schwaiger M. Possible uses of PET in breast carcinoma. *Acta Med Austriaca* 1997; 24(2): 60-62.
15. Avril N, Dose J, Janicke F. Assessment of axillary lymph node involvement in breast cancer patients with PET using radiolabeled FDG. *J. Natl Cancer Inst* 1996; 88: 1204-1209.
16. Bombardieri E, Crippa F, Maffioli L, Chiti A, Castellani MR, Greco M, et al. Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer: can PET with FDG be considered as the best method?. *Int J Oncol* 1996; 8: 693-699.

17. Avril N, Dose J, Ziegler S, Janicke F, Schwaiger M. Diagnostic evaluation of breast tumors and loco-regional lymph node metastases using PET. *Radiologe* 1997; 37 (9): 741-748.
18. Moon DH, Hoh CK, Silverman DS. Accuracy of whole body FDG PET for the detection of recurrent or metastatic breast carcinoma. *J Nucl Med* 1996; 37: 99.
19. Palmedo H, Bender H, Grunwald F, Mallmann P, Zamora P, Krebs D, et al. Comparison of FDG - PET and ^{99m}Tc MIBI scintimammography in the detection of breast tumours. *Eur J Nucl Med* 1997; 24(9): 1138-45.
20. Maffioli L, Seregni E, Nerini S, Massaron S, Crippa F, Bombardieri E. Breast cancer seeking agents: basic approach. *J Nucl Med* 1997; 41(3): 211-224.
21. Jimenez A, Carreras JL, Montz R, Díaz Rubio E, Pérez Segura P, Meroño E. Comparación de la gammagrafía ósea y la PET-FDG en un caso de mama metastásico. *Rev Esp Med Nucl* 1996; 15,2 (129-130).
22. Cook G, Houston S, Maisey M, Fogelman I. Detection of bone metastases in breast cancer by ¹⁸F-FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. *Eur J Nucl Med* 1997; 24: 881.
23. Schirrmeister H, Rentschler M, Diederichs C, Kotzerke J, Reske SN. Comparison of ¹⁸F-F-PET and ^{99m}Tc-MDP bone scans in patients with cancer. *Eur J Nucl Med* 1997; 24: 972.
24. Yutani K, Uehara T, Nishimura T. Detectability of FDG-PET and MIBI-SPECT to breast tumor. *J Nucl Med* 1997; 38: 68.
25. Ivancevic V, Wolter A, Winzer KJ. Intraindividual comparison of F-¹⁸-Fluorodeoxyglucose and ^{99m}Tc-Tetrofosmin in planar scintimammography and SPECT. *J Nucl Med* 1997; 38: 68-69.
26. Holle LH, Tampert L, Lungkurt S. Investigations of breast tumors with fluorine-¹⁸-fluorodeoxyglucose and SPECT. *J Nucl Med* 1996; 37: 615-622.
27. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-¹⁸-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. *J Clin Oncol* 1998; 16(1): 173-180.
28. Benard F, Alavi A, Alavi JB, Stadtmauer EA. PET-FDG imaging in the restaging of metastatic breast cancer before high dose chemotherapy with autologous stem cell support. *J Nucl Med* 1997; 38: 69.
29. Madariaga P, Pérez-Castejón MJ, Jimenez A, Kiblawi S, Maldonado A, Montz R, et al. Utilidad de la PET con ¹⁸F-FDG en la localización de lesiones tumorales tras elevación de marcadores. *Oncología* 1998 (en prensa).
30. Maldonado A, Lizarraga S, López N, Chiva L, Pérez Carrión R, Braña J, et al. La PET-FDG en la sospecha de recidiva tumoral ante elevación de marcadores tumorales y/o pruebas de imagen convencional negativas. *Rev Esp Med Nucl* 1998 (en prensa).
31. Freifelder R, Karp JS. Dedicated PET scanners for breast imaging. *Phys Med Biol* 1997; 42(12): 2463-2480.
32. Bender H, Kirst J, Palmedo H, Schomburg A, Wagner U, Ruhlmann J, et al. Value of FDG PET in the staging of recurrent breast carcinoma. *Anticancer-Res.* 1997; 17 (3B): 1687-92
33. Ruhlmann J, Oehr P, Bender H, Kozak B, Willkomm P, Schrader M, et al. PET scan in general practice for diagnosis of breast cancer. *Acta Med Austriaca* 1997; 24(2): 63-67.
34. Scharl A, Scheidhauer K, Pietrzyk U, Gohring UJ, Schomacker K. Detection of multifocal breast carcinoma using FDG - PET. *Geburtshilfe Frauenheilkd* 1996; 56(8): 434-7.
35. Petren-Mallmin M, Andreasson I, Ljunggren O, Ahlstrom H, Bergh J, Antoni G, et al. Skeletal metastases from breast cancer: uptake of ¹⁸F-fluoride measures with PET in correlation with CT. *Skeletal Radiol* 1998; 27(2): 72-76.
36. Noh DY, Yun IJ, Kim JS, Kang HS, Lee DS, Chung JK, et al. Diagnostic value of PET for detecting breast cancer. *World J Surg* 1998; 22(3): 223-227.

37. Scheidhauer K, Scharl A., Pietrzyk U, Wagner R, Göhring UJ, Schomäcker K, et al. Qualitative FDG -PET in primary breast cancer:clinical relevance and practicability. *Eur J Nucl Med* 1996; 23: 618-623.
38. Encinas M, Quiñones D, Jiménez A, Maldonado A, Pérez Castejón MJ, Madariaga P, et al. Utilidad de la PET-FDG en un caso de mama metastásico. *Casos clínicos en Patología Tumoral* 1998 (en prensa).
39. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progesterone radiopharmaceuticals for imaging breast cancer. *Anticancer-Res* 1997; 17(3B): 1573-6.
40. Kole AC, Nieweg OE, Pruim J, Paans A, Plukker JT, Hoekstra HJ, et al. Standardized Uptake Value and quantification of metabolism for breast cancer imaging with FDG and L-(11 C) tyrosine PET. *J Nucl Med* 1997; 38 (5): 692-6.
41. Flanagan FL, Dehdashti F, Mortimer JE, Siegel BA, Jonson S, Welch MJ. PET assessment of response to tamoxifen therapy in patients with metastatic breast cancer. *J Nucl Med* 1996; 37: 99.
42. Mortimer JE, Dehdashti F, Siegel BA, JA Katzenellenbogen, P Fracasso, MJ Welch. PET with 2-(F-18) fluoro-2-deoxy-D-glucose and 16 alpha-(F-18)fluoro-17 beta estradiol in breast cancer. Correlation with estrogen receptor status and response to systemic therapy. *Clin Cancer Res* 1996; 2: 933-939.
43. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P,et al. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. *Clin Imaging* 1997; 21(5):332-336.
44. Maublant J. Scintigraphic imaging of breast tumors.*Eur.J.Radiol* 1997; 24(1): 2-10.
45. Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJ. Scintigraphic imaging of breast cancer: a review. *Nucl Med Comm* 1997; 18: 698-709.
46. Bombardieri E, Crippa F, Maffioli L, Greco M. Nuclear Medicine techniques for the study of breast cancer. *Eur J Nucl Med* 1997; 24(7):809-24.
47. Powe JE. PET scanning in breast cancer. *Br J Radiol* 1997; 70(835): 668-70.
48. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J, et al. PET in Oncology: will it replace the other modalities?. *Semin Nucl Med* 1997; 27(2): 94-106.
49. Van Eijck CH, Krenning EP, Kvols LK. Nuclear Medicine imaging of breast cancer. *Nucl Med Commun* 1996; 17(11): 925-7.
50. Wahl RL. Nuclear Medicine techniques in breast imaging. *Semin Ultrasound-CT-MR*. 1996; 17(5): 494-505.
51. Ziegler J. New techniques promise improved breast imaging. *J Natl Cancer Inst*. 1996; 88 (21):1518-21.
52. Bombardieri E, Crippa F, Maffioli L, Greco M. Nuclear Medicine techniques for the study of breast cancer. *Eur J Nucl Med* 1997; 24: 809-824.
53. Encinas M, Jimenez A, Pérez-Castejón MJ, Gorospe E, Montz R, Maldonado A, et al. La tomografía de positrones en el cáncer de mama. *Ciencia Ginecológica* 1998; 2 (1) (en prensa).
54. Romer W, Avril N, Dose J, Ziegler S, Kuhn W, Herz M, et al. Metabolic characterization of ovarian tumors with PET and 18F- FDG. *Rofo-Fortschr-Geb-Rontgenstr-Neuen-Bildgeb-Verfahr* 1997; 166(1): 62-8.
55. Zimmy M, Schroder W, Wolters W, Cremerius U, Rath W, Bull U. FDG - PET in ovarian carcinoma. Methodology and preliminary results. *Nuklearmed* 1997; 36 (7): 228-233.40.
56. Börner AR, Weckesser M, Nitz U, et al. F-18-FDG PET in comparison to CT in ovarian cancer. *Eur J Nucl Med* 1997; 24: 1049.
57. Hebart H, Erley C, Kaskas B, Mayer R, König M, Einsele H,et al. PET helps to diagnose tumor emboli and residual disease in choriocarcinoma. *Ann Oncol* 1996; 7 (4): 416-18.